Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Herzog Thomas, Professor
University of Cincinnati Medical Center/USA/1010
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Obstetrics & Gynecology Hospital, Capital Medical University
Beijing, China
- Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
- Peking University Cancer Hospital
Beijing, China
- Chongqing University Cancer Hospital
Chongqing, China
- Sun Yat-Sen University Cancer Center
Guangdong, China
- Harbin Medical University Cancer Hospital
Heilongjiang, China
- Henan Cancer Hospital
Henan, China
- Hubei Cancer Hospital
Hubei, China
- Hunan Cancer Hospital
Hunan, China
- Jilin Cancer Hospital
Jilin City, China
- Liaoning Cancer Hospital
Liaoyang, China
- Qilu Hospital of Shandong University
Shandong, China
- Obstetrics & Gynecology Hospital of Fudan University
Shanghai, China
- Zhongshan Hospital Affiliated To Fudan University
Shanghai, China
- West China Second University Hospital,sichuan University
Sichuan, China
- the Second Hospital of Tianjin Medical University
Tianjin, China
- Women'S Hospital School of Medicine Zhejiang University
Zhejiang, China
- Arizona Oncology Associates
Phoenix, Arizona, United States
- Arizona Oncology
Tucson, Arizona, United States
- Highlands Oncology Group
Rogers, Arkansas, United States
- Gynecology Oncology Associates Newport Beach
Newport Beach, California, United States
- Rocky Mountain Cancer Centers
Littleton, Colorado, United States
- Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, United States
- University of Chicago
Chicago, Illinois, United States
- Women'S Cancer Care
Covington, Louisiana, United States
- Tufts Medical Center
Boston, Massachusetts, United States
- University of Massachusetts
Worcester, Massachusetts, United States
- Nebraska Methodist Hospital
Omaha, Nebraska, United States
- Md Anderson Cancer Center at Cooper
Camden, New Jersey, United States
- Holy Name Medical Center
Teaneck, New Jersey, United States
- Southwest Women'S Oncology Group
Albuquerque, New Mexico, United States
- Montefiore Medical Center
The Bronx, New York, United States
- Ohcare Oncology Hematology Care (ohc), Inc. - Kenwood Office
Cincinnati, Ohio, United States
- University of Cincinnati Medical Center
Cincinnati, Ohio, United States
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
- Abington Memorial Hospital
Willow Grove, Pennsylvania, United States
- Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States
- Texas Oncology
Austin, Texas, United States
- Texas Oncology
Fort Worth, Texas, United States
- Houston Methodist Hospital
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Jun 2020
- Primary completion
- 31 Jul 2023
- Completion
- 28 Jun 2024
- Last update posted
- 10 Sept 2025
- Registered enrollment
- 150
- Registry id
- NCT04374630
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.